ライフサイエンスコーパス: cyclin-dependent kinase 2

1 RK2 and the cell cycle control enzyme, Cdk2 (cyclin-dependent kinase 2).

2 edict progression of DN, downregulated CDK2 (cyclin-dependent kinase 2).

3 (1) phase and thereby prevents activation of cyclin-dependent kinase 2.

4 entry of quiescent T cells is dependent upon cyclin-dependent kinase 2.

5 he G(1)/S transition through inactivation of cyclin-dependent kinase 2.

6 and decreased levels of cyclins A and D and cyclin-dependent kinase 2.

7 and p21(WAF1), and had decreased activity of cyclin-dependent kinase 2.

8 ression of cyclins A and E but a decrease in cyclin-dependent kinase 2.

9 duction in the availability of cyclin D2 and cyclin-dependent kinase 2.

10 1 reverse transcriptase, p38 MAP kinase, and cyclin-dependent kinase 2.

11 evels and binding of p21cip1 to cyclin A and cyclin-dependent kinase-2.

12 A and protein levels of cyclins (D1, E1) and cyclin-dependent kinases (2, 4, and 6).

13 ecting expression of cyclin D2, cyclin E, or cyclin-dependent kinases 2, 4 or 6.

14 Furthermore, cyclin-dependent kinases 2, 4, and 6 showed an opposite

15 Cyclin D1/D3 and cyclin-dependent kinase 2/4 (cdc2/cdc4) were downregulat

16 Cyclin-dependent kinase 2 activated by cyclin E is invol

17 y in FADDdd T cells, cyclin E expression and cyclin-dependent kinase 2 activation were markedly impai

18 ataset of 17 550 compounds and corresponding cyclin-dependent kinase-2 activities showed that informa

19 ly significant as evidenced by inhibition of cyclin-dependent kinase 2 activity and decreased cell pr

20 UCN-01 prevented the increase of cyclin A/cyclin-dependent kinase 2 activity induced by CPT and en

21 tor p27(kip1) was decreased in TR cells, and cyclin-dependent kinase 2 activity was increased.

22 ger-term progression through the cell cycle (cyclin-dependent kinase 2 activity).

23 tive PLK4 following deregulation of cyclin E/cyclin-dependent kinase 2 activity, as is frequently obs

24 sion prevented the PTEN-induced reduction of cyclin-dependent kinase 2 activity, indicating that p27K

25 ence of PTTG were associated with suppressed cyclin-dependent kinase 2 activity, Rb phosphorylation,

26 imposed by p27(kip1)-mediated inhibition of cyclin-dependent kinase 2 activity.

27 n of cyclin A-associated kinase activity and cyclin-dependent kinase 2 activity.

28 endent kinase-I p21(Waf-1) and inhibition of cyclin-dependent kinase 2 activity.

29 into DNA was significantly inhibited, as was cyclin-dependent kinase 2 activity.

30 egulation, leading to inhibition of cyclin E/cyclin-dependent kinase 2 activity.

31 , CPT increased cyclin A levels and cyclin A/cyclin-dependent kinase 2 activity.

32 ated with lack of p21 induction and enhanced cyclin-dependent kinase 2 activity.

33 n-dependent kinase inhibitor p21 and reduced cyclin-dependent kinase 2 activity.

34 reased p27, reduced cyclin A1 and attenuated cyclin-dependent kinase 2 activity.

35 oma tumor suppressor pRb and is dependent on cyclin-dependent kinase 2 activity.

36 to the G1 restriction point, which inhibits cyclin-dependent kinase-2 activity and phosphorylation o

37 er members of the growth regulatory complex, cyclin dependent kinase 2 and cyclin A, but not prolifer

38 clear receptors and transcription factors to cyclin-dependent kinase 2 and Bcl2 family members.

39 50 and 55 and phosphorylation of vimentin by cyclin-dependent kinase 2 and cAMP-dependent protein kin

40 The genes coding for cyclin D1, cyclin D2, cyclin-dependent kinase 2 and Culin3 are stimulated by c

41 hich subsequently enhanced the expression of cyclin-dependent kinase 2 and cyclin E.

42 howed that silibinin decreases the levels of cyclin-dependent kinase 2 and cyclin-dependent kinase 4

43 reas ultraviolet-B exposure had no effect on cyclin-dependent kinase 2 and cyclin-dependent kinase 6

44 Cyclin-dependent kinase 2 and other kinases associated w

45 n was dependent on dissociation of p130 from cyclin-dependent kinase 2 and p130 dephosphorylation.

46 increases the levels and phosphorylation of cyclin-dependent kinase 2 and the retinoblastoma protein

47 ation was not associated with suppression of cyclin-dependent kinases 2 and 4 activity but rather wit

48 phosphorylation is driven by the actions of cyclin-dependent kinases 2 and 4/6 at G1/S cell-cycle ch

49 The protein expression of cyclin-dependent kinases 2 and 6 and Cdc2 was also decre

50 ting cell nuclear antigen (PCNA), Ki-67, and cyclin-dependent kinases-2 and -4.

51 dual-specific phosphatases, reticulon-4, and cyclin-dependent kinase 2) and suggested specific tempor

52 tains Skp2 itself, p27(kip1) (p27), cyclin E-cyclin dependent kinase 2, and the retinoblastoma protei

53 clear p27kip1 is an established inhibitor of cyclin-dependent kinase-2, and it now appears that cytop

54 p53-activating peptide (DV3-TATp53C') and a cyclin-dependent kinase 2 antagonist peptide (DV3-TAT-Rx

55 ter at maternal centrioles requires cyclin E/cyclin-dependent kinase 2 as well as Polo-like kinase 4

56 Kinases known to phosphorylate BRCA1 include cyclin-dependent kinase 2, as well as ataxia telangiecta

57 y still increases the amount of cyclin A and cyclin-dependent kinase 2-associated kinase activity in

58 f p21 and p27 with a concomitant decrease in cyclin-dependent kinase 2-associated kinase activity.

59 We show that cyclin-dependent kinase 2-associated protein 1 (CDK2AP1)

60 Cyclin-dependent Kinase 2-associated Protein 1 (CDK2AP1)

61 CDK2AP1 (cyclin-dependent kinase 2-associated protein 1), corresp

62 l experimental data indicating that Cdk2ap1 (cyclin-dependent kinase 2-associating protein 1), an inh

63 Inhibition of cyclin-dependent kinase 2 by p27(Kip1) is believed to be

64 f Cdc25A, and decreased activity of cyclin E-cyclin-dependent kinase 2; by 4 h, a continued delay at

65 Here, we show that Caenorhabditis elegans cyclin-dependent kinase 2 (CDK-2) partners with cyclin-l

66 An increase in cyclin-dependent kinase 2 (cdk-2) protein expression occ

67 SK-3beta and an enhanced selectivity against cyclin-dependent kinase 2 (CDK-2).

68 crease in the p27(Kip1) level, inhibition of cyclin-dependent kinase-2 (CDK-2) activity, dephosphoryl

69 ted retinoblastoma protein by inhibiting the cyclin-dependent kinase-2 (CDK-2) activity.

70 IFN alpha treatment of DU145 cells reduced cyclin dependent kinase 2 (cdk2) activity.

71 se of very large sets of X-ray structures of cyclin dependent kinase 2 (CDK2) and heat shock protein

72 on of fragment-based screening techniques to cyclin dependent kinase 2 (CDK2) identified multiple (>3

73 The cyclin dependent kinase 2 (Cdk2) is required for initiat

74 Cyclin dependent kinase 2 (CDK2) is the major kinase tha

75 omain-containing protein 1 (EHD1), promoting cyclin dependent kinase 2 (CDK2) phosphorylation and cel

76 Cyclin dependent kinase 2 (CDK2) regulates cell cycle an

77 res of trisubstituted purines complexed with cyclin dependent kinase 2 (cdk2), a protein important in

78 Since cyclin dependent kinase 2 (CDK2)/cyclin E triggers DNA s

79 sphates from threonine-14 and tyrosine-15 of cyclin dependent kinase-2 (cdk2) in vitro, and it is the

80 ted cells were characterized by a decline in cyclin-dependent kinase 2 (CDK2) activities, loss of hyp

81 1,25-VD treatment inhibited cyclin-dependent kinase 2 (cdk2) activity and induced G0

82 ed S-phase entry is accompanied by increased cyclin-dependent kinase 2 (CDK2) activity as well as dec

83 revious studies concluded that FB1 repressed cyclin-dependent kinase 2 (CDK2) activity but induced CD

84 G1 arrest brought about by an inhibition of cyclin-dependent kinase 2 (Cdk2) activity by p27(kip1).

85 we use single-cell time-lapse microscopy of Cyclin-Dependent Kinase 2 (CDK2) activity followed by en

86 sent study, we report that downregulation of cyclin-dependent kinase 2 (cdk2) activity in serum-depri

87 ing of a mouse strain carrying a reporter of cyclin-dependent kinase 2 (CDK2) activity showed that B

88 imulated HUVEC caused a decrease in cyclin E-cyclin-dependent kinase 2 (cdk2) activity with resulting

89 expression of p27Kip1, inhibition of cyclin/cyclin-dependent kinase 2 (cdk2) activity, accumulation

90 Cyclin A-cyclin-dependent kinase 2 (CDK2) activity, but not cycli

91 is partially required for the inhibition of cyclin-dependent kinase 2 (Cdk2) activity, cyclin A expr

92 nase inhibitor p27Kip1 levels, inhibition of cyclin-dependent kinase 2 (Cdk2) activity, hypophosphory

93 fect on the G(1)-S transition and stimulated cyclin-dependent kinase 2 (Cdk2) activity.

94 d levels of cyclin E protein and deregulated cyclin-dependent kinase 2 (CDK2) activity.

95 est was attributed to inhibition of G1-phase cyclin-dependent kinase 2 (CDK2) activity.

96 vent model to study the interactions between cyclin-dependent kinase 2 (CDK2) and analogues of the cl

97 xpression of cell cycle genes that stimulate cyclin-dependent kinase 2 (Cdk2) and Cdk1 activity.

98 cycle arrest is attributed to inhibition of cyclin-dependent kinase 2 (CDK2) and concomitant dephosp

99 E1 (CcnE1) is the regulatory subunit of the cyclin-dependent kinase 2 (Cdk2) and controls cell cycle

100 structural conservation in interactions with cyclin-dependent kinase 2 (Cdk2) and cyclin A.

101 ll lines by regulating the expression of the cyclin-dependent kinase 2 (CDK2) and cyclin D1 proteins.

102 l activation due to impaired accumulation of cyclin-dependent kinase 2 (Cdk2) and cyclin E.

103 of miR-181c significantly inhibited phospho-cyclin-dependent kinase 2 (CDK2) and cyclin-A expression

104 Activation of cyclin-dependent kinase 2 (cdk2) and cyclin-dependent ki

105 trosome duplication requires the activity of cyclin-dependent kinase 2 (Cdk2) and cyclins E and A [7-

106 hase of cell cycle, elevation of Cylin E and Cyclin-dependent kinase 2 (CDK2) and downregulation of p

107 lls, two E-type cyclins, E1 and E2, activate cyclin-dependent kinase 2 (CDK2) and drive cell cycle pr

108 saccharomyces pombe and are similar to human cyclin-dependent kinase 2 (CDK2) and extracellular signa

109 nteracting proteins controls the activity of cyclin-dependent kinase 2 (Cdk2) and governs the entry o

110 on of p21(Waf1/Cip1); p21, in turn, binds to cyclin-dependent kinase 2 (cdk2) and inhibits its functi

111 This aptamer binds to cyclin-dependent kinase 2 (Cdk2) and inhibits its kinase

112 tion of EGFR and Neu signaling, reduction of cyclin-dependent kinase 2 (Cdk2) and mitogen-activated p

113 TEN) pathway reversed quiescence by inducing cyclin-dependent kinase 2 (CDK2) and reducing p21(CIP1)

114 teins interacting with human SAMHD1, namely, cyclin-dependent kinase 2 (CDK2) and S-phase kinase-asso

115 Here we report that changes in the levels of cyclin-dependent kinase 2 (CDK2) and the cell cycle inhi

116 Cyclic strain increased the activity of cyclin-dependent kinase 2 (cdk2) and the cellular level

117 could disrupt the interaction between cyclin/cyclin-dependent kinase 2 (cdk2) and the E2F repressor c

118 o]-6,7-dimethoxyquinazoline) in complex with cyclin-dependent kinase 2 (CDK2) and the other (4-[3-met

119 s a positive feedback loop between cyclin A2/cyclin-dependent kinase 2 (CDK2) and the retinoblastoma

120 Furthermore, we identified cyclin-dependent kinase 2 (CDK2) as a direct kinase phos

121 53, was cloned by expression cloning through cyclin-dependent kinase 2 (CDK2) association.

122 rsion of p21 was capable of interacting with cyclin-dependent kinase 2 (Cdk2) but failed to inhibit i

123 e phosphorylation of pRb, activates cyclin E-cyclin-dependent kinase 2 (cdk2) by titrating Cip/Kip cd

124 The cyclin E-cyclin-dependent kinase 2 (CDK2) complex accelerates ent

125 domain bound to the phosphorylated cyclin A-cyclin-dependent kinase 2 (Cdk2) complex has been determ

126 Cyclin-dependent kinase 2 (CDK2) complex is significantl

127 is likely that it downregulates the cyclin A-cyclin-dependent kinase 2 (CDK2) complex, which is requi

128 on binding with the phosphorylated cyclin A-cyclin-dependent kinase 2 (Cdk2) complex.

129 c-Myc may stimulate the activity of cyclin E/cyclin-dependent kinase 2 (Cdk2) complexes and antagoniz

130 Cyclin D1/cyclin-dependent kinase 2 (Cdk2) complexes are present a

131 sically associates with E- and A-type cyclin/cyclin-dependent kinase 2 (Cdk2) complexes through a cyc

132 Expression of cyclin E and cyclin-dependent kinase 2 (cdk2) correlated with the pro

133 The arrested cells contain inactive cyclin-dependent kinase 2 (cdk2) despite the presence of

134 Cyclin-dependent kinase 2 (CDK2) drives the progression

135 a promising avenue for cancer therapy, with cyclin-dependent kinase 2 (CDK2) emerging as a key targe

136 llagen promoter, whereas a dominant-negative cyclin-dependent kinase 2 (cdk2) enhanced repression by

137 pression is correlated with higher levels of cyclin-dependent kinase 2 (Cdk2) enzymatic activity in v

138 els in the small intestinal mucosa increases cyclin-dependent kinase 2 (CDK2) expression and stimulat

139 as evidenced by increased histone 3 mRNA and cyclin-dependent kinase 2 (cdk2) expression, and this is

140 Here we show that the G1/S phase-related cyclin-dependent kinase 2 (CDK2) gene is a novel prolife

141 Cyclin-dependent kinase 2 (CDK2) has been proposed to fu

142 the cell cycle control proteins cyclin E and cyclin-dependent kinase 2 (CDK2) in carotids of apolipop

143 -dependent colocalization of MEQ protein and cyclin-dependent kinase 2 (CDK2) in coiled bodies and th

144 e late G1/S cell-cycle proteins cyclin E and cyclin-dependent kinase 2 (cdk2) in human islets.

145 has been implicated as a target for cyclin E/cyclin-dependent kinase 2 (CDK2) in modulating centrosom

146 We investigated the function of cyclin-dependent kinase 2 (Cdk2) in neural progenitor ce

147 otent, highly selective, orally bioavailable cyclin-dependent kinase 2 (CDK2) inhibitor in clinical d

148 hibition of NF90 sensitized HCC cells to the cyclin-dependent kinase 2 (CDK2) inhibitor, roscovitine.

149 Cyclin-dependent kinase 2 (CDK2) inhibitors have recentl

150 Cyclin-dependent kinase 2 (CDK2) is a known regulator in

151 Cyclin-dependent kinase 2 (CDK2) is a potential therapeu

152 Cyclin-dependent kinase 2 (cdk2) is a small serine/threo

153 Cyclin-dependent kinase 2 (CDK2) is a target for many th

154 Although cyclin-dependent kinase 2 (CDK2) is a validated target f

155 eracetylated, levels of p27 are reduced, and cyclin-dependent kinase 2 (CDK2) is activated upon SIRT1

156 Cyclin-dependent kinase 2 (Cdk2) is essential for initia

157 The activity of cyclin-dependent kinase 2 (CDK2) is essential for progre

158 Cyclin-dependent kinase 2 (CDK2) is known to localize to

159 Whereas cyclin-dependent kinase 2 (Cdk2) is not necessary for mo

160 The function of cyclin-dependent kinase 2 (CDK2) is often abolished afte

161 Cyclin-dependent kinase 2 (Cdk2) is required for multipl

162 horylation of p27 on threonine 187 (T187) by cyclin-dependent kinase 2 (Cdk2) is thought to initiate

163 lizes NPAT/p220, a substrate of the cyclin E/cyclin-dependent kinase 2 (CDK2) kinase complex, as a ke

164 Cyclin-dependent kinase 2 (Cdk2) mediates this suppressi

165 nd show that its phosphorylation by cyclin A-cyclin-dependent kinase 2 (CDK2) on a novel site, serine

166 the human NPM's phosphorylation by cyclin E-cyclin-dependent kinase 2 (cdk2) on threonine (Thr) 199

167 further revealed that the phosphorylation of cyclin-dependent kinase 2 (CDK2) on threonine-160 mediat

168 ading does not result from downregulation of cyclin-dependent kinase 2 (Cdk2) or Cdc7 activity and is

169 eviously, we and others report that cyclin E/cyclin-dependent kinase 2 (CDK2) phosphorylates enhancer

170 Cyclin E-associated kinase and cyclin-dependent kinase 2 (cdk2) phosphorylation are inh

171 Human UHRF1 contains a conserved cyclin-dependent kinase 2 (CDK2) phosphorylation site at

172 ed a specific PTPN12-insert-loop harboring a cyclin-dependent kinase 2 (CDK2) phosphorylation site.

173 Cyclin-dependent kinase 2 (cdk2) plays a critical role i

174 The cellular cyclin-dependent kinase 2 (CDK2) plays a major role in H

175 Cyclin-dependent kinase 2 (CDK2) plays an important role

176 by modulating the activities of cyclin E and cyclin-dependent kinase 2 (cdk2) proteins and their comp

177 Kinetic analysis establishes that Cyclin-dependent kinase 2 (CDK2) requires simultaneous b

178 -P; gene symbol HINFP) bound to its cyclin E/cyclin-dependent kinase 2 (CDK2) responsive coactivator

179 his was achieved for compounds targeting the cyclin-dependent kinase 2 (CDK2) substrate recruitment s

180 Since cyclin-dependent kinase 2 (CDK2) triggers initiation of

181 essed by plasmids encoding human cyclins and cyclin-dependent kinase 2 (CDK2) were used as antigens i

182 med hepatocytes is regulated by complexes of cyclin-dependent kinase 2 (Cdk2) with E-type cyclins (Cc

183 ght to determine if reducing the activity of cyclin-dependent kinase 2 (CDK2) with the purine analogu

184 Cyclin-dependent kinase 2 (CDK2), a known modulator of t

185 To support drug discovery efforts for cyclin-dependent kinase 2 (CDK2), a moderate-throughput

186 Inhibition of cyclin-dependent kinase 2 (CDK2), a positive regulator o

187 ect on pol-alpha:primase or by its effect on cyclin-dependent kinase 2 (CDK2), a recently identified

188 The two E-cyclins share a catalytic partner, cyclin-dependent kinase 2 (CDK2), and activate their ass

189 decreased expression of cyclin D1, cyclin E, cyclin-dependent kinase 2 (cdk2), and cdk4.

190 where they bind the cyclin E kinase partner, cyclin-dependent kinase 2 (Cdk2), and have associated ki

191 showed that CycE and its canonical partner, Cyclin-dependent kinase 2 (Cdk2), are required not only

192 ncreased p21 expression and association with cyclin-dependent kinase 2 (CDK2), CDK4 and proliferating

193 anied by acquisition of new partners such as cyclin-dependent kinase 2 (cdk2), cdk4, and cdk6 in infe

194 companied by cell cycle arrest, with reduced cyclin-dependent kinase 2 (Cdk2), Cdk4, Aurora kinase A,

195 Here, we show that the cell cycle regulator, cyclin-dependent kinase 2 (CDK2), couples primary beta-c

196 In vitro, LSF is phosphorylated by cyclin E/cyclin-dependent kinase 2 (CDK2), cyclin C/CDK2, and cyc

197 ssociated with Cell Division Cycle 6 (CDC6), Cyclin-dependent kinase 2 (CDK2), Cyclins D1 and D3, ind

198 Cyclin E, a regulatory subunit of cyclin-dependent kinase 2 (Cdk2), is an important regula

199 Cyclin E, an activator of cyclin-dependent kinase 2 (Cdk2), is targeted for protea

200 Expression of the cyclin-dependent kinase 2 (CDK2), itself a downstream ta

201 7Xic1 and reduces its ability to inhibit the cyclin-dependent kinase 2 (Cdk2), leading to shortening

202 y eight inhibitors of three protein kinases, cyclin-dependent kinase 2 (CDK2), lymphocyte-specific ki

203 E, in conjunction with its catalytic partner cyclin-dependent kinase 2 (CDK2), regulates cell cycle p

204 on for SARS-CoV-2 main protease (M(pro)) and Cyclin-dependent Kinase 2 (CDK2), respectively.

205 tion of the pro-oncogenic proteins cyclin E, cyclin-dependent kinase 2 (CDK2), Skp2, and Cdt1.

206 to both DNA polymerase alpha/primase and to cyclin-dependent kinase 2 (CDK2), thereby inhibiting the

207 The transcription factor E2F activates cyclin-dependent kinase 2 (CDK2), which in turn phosphor

208 sid packages a host cell protein kinase, the cyclin-dependent kinase 2 (CDK2), which is thought to be

209 Importantly, restoration of cyclin-dependent kinase 2 (CDK2)-cyclin A and thus PCNA

210 matography indicated that LRP interacts with cyclin-dependent kinase 2 (cdk2)-cyclin complexes or cdc

211 Activation of cyclin-dependent kinase 2 (CDK2)-cyclin E in the late G(

212 The kinase activity of cyclin-dependent kinase 2 (CDK2)-cyclin E is required fo

213 by the late G1 phase-specific activation of cyclin-dependent kinase 2 (CDK2)-cyclin E, which trigger

214 e elicited cell division cycle 7 (CDC7)- and cyclin-dependent kinase 2 (CDK2)-dependent reactivation

215 d degradation, a process directed in part by cyclin-dependent kinase 2 (CDK2)-mediated phosphorylatio

216 and this correlates with changes in cyclin E-cyclin-dependent kinase 2 (CDK2)-specific activity, cycl

217 t in S-phase that involved the inhibition of cyclin-dependent kinase 2 (Cdk2).

218 azolylthio acetic ester 1 as an inhibitor of cyclin-dependent kinase 2 (CDK2).

219 DNA synthesis, we investigated its effect on cyclin-dependent kinase 2 (CDK2).

220 indol-2-ones, were shown to potently inhibit cyclin-dependent kinase 2 (CDK2).

221 h, and activating its catalytic partner, the cyclin-dependent kinase 2 (Cdk2).

222 osine triphosphate-binding site of the human cyclin-dependent kinase 2 (CDK2).

223 re co-expressed with their catalytic partner cyclin-dependent kinase 2 (Cdk2).

224 e cell cycle in human cell lines that target cyclin-dependent kinase 2 (CDK2).

225 RP1-T449 as a SAMe-sensitive phospho-site of cyclin-dependent kinase 2 (CDK2).

226 ptotic death of cardiomyocytes by activating cyclin-dependent kinase 2 (CDK2).

227 on of p27Kip1 (p27), a negative regulator of cyclin-dependent kinase 2 (Cdk2).

228 f phosphorylation sites on recombinant human cyclin-dependent kinase 2 (CDK2).

229 T479 at the Akt extreme carboxy terminus by cyclin-dependent kinase 2 (Cdk2)/cyclin A or mTORC2, und

230 an alpha-helical structure, upon binding to cyclin-dependent kinase 2 (Cdk2)/cyclin A.

231 and the LR protein (LRP) is associated with cyclin-dependent kinase 2 (Cdk2)/cyclin complexes during

232 First, tetrandrine inhibits purified cyclin-dependent kinase 2 (CDK2)/cyclin E and CDK4 witho

233 Upon phosphorylation on Thr(199) by cyclin-dependent kinase 2 (CDK2)/cyclin E, the majority

234 of p21WAF1/CIP1 in complexes of p21WAF1/CIP1/cyclin-dependent kinase 2 (cdk2)/cyclin showed that the

235 p27 functions in the nucleus to suppress cyclin-dependent kinase-2 (Cdk2) activity and has been r

236 in TCDD-treated mice correlated with reduced cyclin-dependent kinase-2 (CDK2) activity, a pivotal reg

237 profoundly inhibited cyclin E expression and cyclin-dependent kinase-2 (CDK2) activity, but not D-typ

238 n between OP proliferation rate and cyclin E/cyclin-dependent kinase-2 (cdk2) activity.

239 ssion and attenuated pRb phosphorylation and cyclin-dependent kinase-2 (CDK2) activity.

240 e show that activation of the human E2F1 and cyclin-dependent kinase-2 (CDK2) promoters requires elem

241 Here we describe regulation of the cyclin-dependent kinase-2 (CDK2) protein, an enzyme that

242 -ylamines as moderately potent inhibitors of cyclin-dependent kinase-2 (CDK2), a CDK inhibitor analog

243 p-1 binding and decrease p27kip-1 binding to cyclin-dependent kinase-2 (cdk2), an enzyme required for

244 ic, cicaprost, selectively inhibits cyclin E-cyclin-dependent kinase-2 (Cdk2), and now we show that i

245 esponds to the increased binding of p21 with cyclin-dependent kinase-2 (Cdk2), and the decreased Cdk2

246 le inhibitors-p16, p21, or dominant-negative cyclin-dependent kinase-2 (Cdk2).

247 rrest, caused primarily by the inhibition of cyclin-dependent-kinase 2 (cdk2), is a critical step in

248 ramatic up-regulation of cyclin A-associated cyclin-dependent kinase 2(cdk2) activity.

249 The 2.6 Angstrom crystal structure for human cyclin-dependent kinase 2(CDK2) in complex with CksHs1,

250 1- and p27-mediated inactivation of cyclin E-cyclin-dependent kinase 2 complex kinase activity.

251 S phase block cannot fully saturate cyclin A-cyclin-dependent kinase 2 complexes and does not interac

252 Cyclin E/cyclin-dependent kinase 2 complexes are essential during

253 ivate the cyclin A promoter, induce cyclin A-cyclin-dependent kinase 2 complexes, and promote cycling

254 h the N112C mutant and wild-type CCNE1:CDK2 (cyclin-dependent kinase 2) complexes.

255 its S phase entry by binding to cyclin-cdk2 (cyclin-dependent kinase-2) complexes.

256 Specifically, binding of Cks1 or Cks2 to cyclin-dependent kinase 2 confers partial resistance to

257 en (OHT) leads to the activation of Cyclin E/Cyclin-dependent kinase 2 (CycE/Cdk2) complexes followed

258 2 and DACAPO (DAP), an inhibitor of Cyclin E/cyclin-dependent kinase 2 (CycE/cdk2).

259 OH-terminal region of p300 binds to cyclin E-cyclin-dependent kinase 2 (cyclin E-Cdk2) and TFIIB, as

260 on were blocked by selective inactivation of cyclin-dependent kinase 2-cyclin E (Cdk2-E) and were res

261 ll plates, to measure direct binding between cyclin-dependent kinase 2/cyclin E complex (CDK2/E) and

262 with Src family kinases and an inhibitor of cyclin dependent kinase 2, demonstrating that high-throu

263 kinase inhibitor, expression of cyclin A and cyclin-dependent kinase 2, DNA replication, MCE, and, su

264 hthalmia-associated transcription factor and cyclin dependent kinase 2 expression.

265 p2 targets beta-TrCP for degradation via the cyclin-dependent kinase 2-facilitated recognition of the

266 sphatidylinositol 3-kinase, calcineurin, and cyclin-dependent kinase 2 has facilitated the elucidatio

267 ndicating that p27Kip1 functions upstream of cyclin-dependent kinase 2 in the PTEN regulatory cascade

268 Addition of the cyclin-dependent kinase 2 inhibitor p21(cip1) specifical

269 ition, zorifertinib combined with AZD5438 (a cyclin-dependent kinase 2 inhibitor) synergistically pre

270 stress that occurs via downregulation of the cyclin-dependent kinase 2 interacting protein (CINP), le

271 Cyclin-dependent kinase 2 is a serine/threonine protein

272 The activity of cyclin-dependent kinase 2 is required for G(1)-S-phase p

273 ncreased expression of p21 and inhibition of cyclin-dependent kinase 2 kinase activity by FP was also

274 e G1/S transition, and the activity of cdk2 (cyclin-dependent kinase 2) kinase is impaired by the con

275 lation of TP63 expression and phosphorylated cyclin-dependent kinase 2 levels.

276 r selectivity were investigated by producing cyclin-dependent kinase 2 mutants bearing equivalent cyc

277 orylation of Rb and the activity of cyclin E-cyclin-dependent kinase 2 on IL-2 signaling.

278 Cyclin E and its co-activator, phospho-cyclin-dependent kinase 2 (p-CDK2), regulate G1 to S pha

279 icity of protein tyrosine phosphatase N12 by cyclin-dependent kinase 2 phosphorylation orchestrating

280 ened cyclin-dependent kinase inhibitor (CKI)-cyclin-dependent kinase 2 positive-feedback loop, normal

281 ression of transforming growth factor beta1, cyclin-dependent kinase 2, protein kinase C betaII and e

282 Kinase activities of cyclin E and cyclin-dependent kinase 2 responsible for the G(1)-S tra

283 Use of the cyclin-dependent kinase 2-selective 6-cyclohexylmethoxy-

284 ation inhibits the phosphorylation of pRB at cyclin-dependent kinase 2-specific, but not cyclin-depen

285 pus laevis Tipin as a substrate for cyclin E/cyclin-dependent kinases 2 that is phosphorylated in int

286 decreased steady-state levels and binding of cyclin-dependent kinase-2 to cyclin A and increased stea

287 lzheimer's-disease-associated protein Tau by cyclin-dependent kinase 2 was accelerated within condens

288 ad, and annexin I were induced; cyclin E and cyclin-dependent kinase 2 were repressed; and bcl-2 and

289 g Cip1 and Kip1 genes encoding inhibitors of cyclin-dependent kinase-2 were used to further explore t

290 xpression levels of bMSTN-mut, P21 and CDK2 (cyclin dependent kinase 2) were examined with qPCR and W

291 crucial role in the cell cycle by activating cyclin-dependent kinase 2, which phosphorylates Rb, lead

292 y dephosphorylation of pRb and inhibition of cyclin-dependent kinase 2, which results in part from in

293 The approach is illustrated by mapping cyclin-dependent kinase 2, which successfully identifies

294 on, only the generic CCRK phosphorylates the cyclin-dependent kinase 2, which was accompanied by a do